Annexon (NASDAQ:ANNX) EVP Ted Yednock Sells 7,857 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 7,857 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total transaction of $40,149.27. Following the sale, the executive vice president owned 97,227 shares of the company’s stock, valued at approximately $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Annexon Trading Down 3.9%

ANNX stock traded down $0.20 during trading on Friday, reaching $4.90. 1,749,100 shares of the stock were exchanged, compared to its average volume of 1,986,881. The firm has a market capitalization of $586.19 million, a price-to-earnings ratio of -3.48 and a beta of 1.17. The business has a 50 day moving average price of $5.58 and a 200-day moving average price of $3.94. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $7.18.

Key Annexon News

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in Annexon during the 2nd quarter worth approximately $29,000. 49 Wealth Management LLC purchased a new stake in shares of Annexon during the second quarter worth $29,000. CIBC Bancorp USA Inc. purchased a new position in Annexon in the third quarter valued at $31,000. Engineers Gate Manager LP acquired a new position in Annexon during the 2nd quarter worth $32,000. Finally, SG Americas Securities LLC acquired a new position in Annexon during the 3rd quarter worth $34,000.

Analysts Set New Price Targets

Several equities analysts have recently commented on ANNX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Wells Fargo & Company boosted their price objective on shares of Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Chardan Capital started coverage on shares of Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.